Search

Filters

Clear Filters
3:30 PM - 3:35 PM PT

120 - 5-Year Results of a Prospective, Non-Randomized Controlled Study: Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate Cancer Patients Receiving Radiotherapy
Speaker: Ma, Mingwei, MD - Peking University First Hospital, Beijing, Beijing
2:30 PM - 2:37 PM PT

121 - Impact of MMR Status vs. Clinicopathologic Risk Factors on Locoregional Recurrence in Stage I Endometrioid Endometrial Cancer Treated with Brachytherapy Alone
Speaker: Hathout, Lara, MD, FRCPC - Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2:37 PM - 2:44 PM PT

122 - Radiation-Induced CTD-2292M14.1 Enhances Cervical Cancer Radioresistance by Promoting P62 Ubiquitination
Speaker: Zhou, Jie, PhD, RT - Sichuan Cancer Hospital and Institute, Chengdu, Sichuan
2:44 PM - 2:51 PM PT

123 - Transcriptomic Profiling Reveals Predictive Markers of Response to Concurrent Chemoradiotherapy plus Immune Checkpoint Inhibition in Cervical Cancer
Speaker: Cao, Yuan Jie, MD, PhD - Tianjin Medical University Cancer Institute and Hospital, Tian Jin, Tian Jin
2:51 PM - 2:58 PM PT

124 - Tracking Changes in B Cell Antibodies in Cervical Cancer Patients Treated with Chemoradiation and Immunotherapy on GOG 9929
Speaker: Kim, Sangwoo, MD - University of California, San Diego, La Jolla, CA
2:58 PM - 3:05 PM PT

125 - Hypofractionated Radiotherapy as a Potential Alternative to Conventional Treatment for Cervical Cancer in Resource-Limited Setting: A Prospective Comparative Analysis
Speaker: Mallum, Abba, MD, PhD - Department of Radiotherapy and Oncology, Inkosi Albert Luthuli Central Hospital, Durban
3:05 PM - 3:12 PM PT

126 - A Real-World Comparison of Moderated Hypofractionated Radiotherapy and Conventional Fractionated Radiotherapy in Cervical Cancer
Speaker: Zeng, Zheng, MD - Peking Union Medical College Hospital, Beijing, Beijing
2:30 PM - 2:40 PM PT

127 - Mid-Treatment ctDNA to Predict Outcomes in Stage IIB-IIIC NSCLC Treated with MRI-Adapted Chemoradiation
Speaker: Hashmi, Ayesha, MD - Mayo Clinic Alix School of Medicine, Rochester, MN
2:40 PM - 2:50 PM PT

128 - Fatal Pulmonary Hemorrhage in Patients Treated with Hypofractionated RT for Stage II-III NSCLC
Speaker: Cooke, Saskia, MD - Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, Noord-Holl
2:50 PM - 3:00 PM PT

129 - Sequential Chemo-Immunotherapy plus Optimized Thoracic Radiotherapy vs. Standard Thoracic Radiotherapy for Elderly and/ or Frail Stage III Non-Small-Cell Lung Cancer: A Randomized Open-Label Controlled Trial of iLCC-3
Speaker: Qi, Wei-Xiang, MD, RT - Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai
3:00 PM - 3:10 PM PT

130 - High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Phase II Immunotherapy Clinical Trials
Speaker: Eustace, Nicholas, MD, PhD - City of Hope National Medical Center, Duarte, CA
3:10 PM - 3:20 PM PT

131 - Gut Microbiota Predictive of Consolidation Immunotherapy Efficacy and Toxicity after Chemoradiotherapy in Lung Cancer
Speaker: Li, Yitong, MD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy, Beijing, Beijing